Evidence map›Paper›PMID 39768345›Full record

ArticleLife (Basel, Switzerland)2024

Diet Supplementation with Ketoanalogues, Inulin, and Calcium Citrate in Chronic Kidney Disease: A Retrospective Cohort.

Martín Calderón-Juárez, Nadia Saavedra-Fuentes, Karla Guadalupe Del Castillo-Loreto, Juan Carlos Castillo-Salinas, Claudia Lerma

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Martín Calderón-JuárezFaculty of Sciences, Universidad Nacional Autónoma de México, Coyoacan 04510, Mexico.ORCID 0000-0003-1438-2188
Nadia Saavedra-FuentesCentro Medico Dalinde, Mexico City 06760, Mexico.ORCID 0009-0002-0198-0410
Karla Guadalupe Del Castillo-LoretoIndependent Practice, Mexico City 06760, Mexico.ORCID 0000-0001-5886-6892
Juan Carlos Castillo-SalinasIndependent Practice, Mexico City 03010, Mexico.ORCID 0009-0002-0611-5311
Claudia LermaDepartment of Molecular Biology, Instituto Nacional de Cardiología Ignacio Chávez, Tlalpan 14080, Mexico.ORCID 0000-0002-4679-7751

Funding

Laboratorios Columbia SA de CV 10112023
6 · The paper itself

Abstract

The addition of ketoanalogues (KAs) to a low-protein diet has been shown to mitigate the progression of pre-dialysis chronic kidney disease (CKD). The addition of inulin and calcium citrate may add further benefits, given their nephroprotective effects. In this study, we tested the changes in estimated glomerular filtration rate (eGFR), CKD symptoms, body composition, and biochemical parameters after 6 months of diet supplementation with Cetolán III, a combination of KA, inulin, and calcium citrate. We included 76 adult patients diagnosed with CKD stages 3 and 4 and not treated with renal replacement therapy in a retrospective cohort. In this cohort, participants were followed through two clinic visits at 3 and 6 months after diet supplementation. We found a slight increase in eGFR at 3 and 6 months compared with baseline, as well as a decrease in the severity of CDK-related symptoms, fat mass, and muscle mass. We observed only a slight decrease in creatinine and uric acid after 6 months of follow-up. We did not find a remarkable change in anthropometric parameters (e.g., body mass index, waist circumference, and arm muscle area). This observational study suggests that addition of KA, inulin, and calcium citrate to a low protein- diet could be associated with an improvement in eGFR and symptom severity in CKD pre-dialysis.

Indexed as

chronic kidney diseaseketoanaloguesretrospective cohort

Identifiers

PMID39768345
PMCPMC11677553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.